

Attorney Docket No.: ISPH-0772  
Inventors: Monia and Wyatt  
Serial No.: 10/659,473  
Filing Date: September 10, 2003  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a 3'-untranslated region of a nucleic acid molecule encoding human PKA regulatory subunit RII beta, wherein said compound specifically hybridizes with said nucleic acid molecule encoding PKA regulatory subunit RII beta to said region and inhibits the expression of human PKA regulatory subunit RII beta.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Attorney Docket No.: ISPH-0772  
Inventors: Monia and Wyatt  
Serial No.: 10/659,473  
Filing Date: September 10, 2003  
Page 3

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (original): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding PKA regulatory subunit RII beta.

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Attorney Docket No.: ISPH-0772  
Inventors: Monia and Wyatt  
Serial No.: 10/659,473  
Filing Date: September 10, 2003  
Page 4

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (original): A method of inhibiting the expression of PKA regulatory subunit RII beta in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of PKA regulatory subunit RII beta is inhibited.

Claims 16-20 (canceled).